Argan insider plans sale of 5,000 shares

Argan, Inc. insider John R. Jeffrey, Jr. has filed a notice of proposed sale of 5,000 shares of common stock through Charles Schwab on or about 01/27/2026, to be sold on the NYSE.

Rhea-AI Filing Summary

Argan, Inc. insider John R. Jeffrey, Jr. has filed a notice of proposed sale of 5,000 shares of common stock through Charles Schwab on or about 01/27/2026, to be sold on the NYSE. The filing lists an aggregate market value for these planned sales of $1,795,400 and notes that 13,873,410 shares of common stock were outstanding.

The shares to be sold are tied to an equity grant of 8,636 common shares acquired on 01/16/2026 via option exercise. The notice also reports that during the prior three months, Jeffrey sold 2,700 shares of common stock on 01/20/2026 for gross proceeds of $1,027,620. By signing, the seller represents that he is not aware of undisclosed material adverse information about Argan’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction is disclosed for Argan (AGX) in this Form 144?

The notice shows John R. Jeffrey, Jr. intends to sell 5,000 shares of Argan, Inc. common stock on or about 01/27/2026 through Charles Schwab on the NYSE, with an aggregate market value listed as $1,795,400.

How many Argan (AGX) shares are outstanding in this filing?

The filing states that 13,873,410 shares of Argan, Inc. common stock were outstanding at the time referenced in the notice.

How did the insider acquire the Argan (AGX) shares being sold?

The document reports that 8,636 common shares were acquired on 01/16/2026 via an equity grant from the issuer, with the nature of payment described as an option exercise on the same date.

What Argan (AGX) insider sales occurred in the prior three months?

The notice lists that John R. Jeffrey, Jr. sold 2,700 shares of Argan common stock on 01/20/2026, reporting gross proceeds of $1,027,620 from that transaction.

Which broker is handling the planned Argan (AGX) share sale?

The proposed sale of 5,000 Argan common shares is to be executed through Charles Schwab & Co. Inc., located at 3000 Schwab Way, Westlake, TX 76262, with the shares to be sold on the NYSE.

What representation does the insider make about Argan (AGX) information?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about Argan’s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 02:16 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001709914
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARGAN, INC.
SEC File Number	001-31756
Address of Issuer	4075 WILSON BOULEVARD SUITE 440 ARLINGTON VIRGINIA 22203
Phone	3013150027
Name of Person for Whose Account the Securities are To Be Sold	John Ronald Jeffrey Jr.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Charles Schwab & Co. Inc. 3000 Schwab Way Westlake TX 76262	5000	1795400	13873410	01/27/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/16/2026	EQUITY GRANT	ISSUER			8636	01/16/2026	OPTION EXERCISE

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John R. Jeffrey, Jr. c/o Argan, Inc. 4075 Wilson Blvd, Suite 440 Arlington VA 22203	Common Stock	01/20/2026	2700	1027620

144: Remarks and Signature

Remarks
Date of Notice	01/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ John R. Jeffrey, Jr.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)